(Updated – August 29, 2023 6:58 AM EDT)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the Company), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Companys near-term priorities and are expected to result in up to $300 million in total cost savings through 2024.
Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, said, We are taking important actions to strengthen our ability to invest in growth opportunities and support the Company’s long-term success, i…
Read the full article at: https://www.streetinsider.com/Corporate News/Apellis Pharmaceuticals (APLS) Announces Corporate Restructuring, Will Cut 25% Staff/22100314.html